BACKGROUND: Although chronic obstructive pulmonary disease (COPD) has been considered a disease of Caucasian men, recent data show mortality rising faster among women and African-Americans. Some have suggested these groups are more susceptible to tobacco smoke. We examined this issue in our own population of COPD patients. METHODS: Beginning in March 2003 we prospectively developed a COPD research database to facilitate recruitment for clinical trials. Enrollees are recruited from clinics and paid advertising and their demographics, medical/smoking histories, and spirometric data are recorded. We examined the smoking histories and pulmonary function of enrollees over 45, with 20 pack-years of smoking, FEV(1)/FVC (forced expiratory volume forced vital capacity) <0.70, and a race-adjusted post-bronchodilator FEV(1)<80%. The primary outcome was the loss of lung function per pack-year smoked, or Susceptibility Index (SI), calculated using the formula: (% predicted FEV(1)-100)/pack-years. RESULTS: A total of 585 patients enrolled during the study period and 330 met our inclusion criteria. Caucasians were older than African-Americans (63 vs. 58, P=0.0003) and had more pack-years of smoking (57 vs. 43, P=0.0003). There were no differences in lung function or bronchodilator reversibility among the racial or gender subgroups. Caucasians had less loss of lung function per pack-year smoked than African-Americans (SI=-1.02% vs. -1.34%, P=0.007) and men less than women (SI=-0.98% vs. -1.21%, P=0.001). Caucasian males appeared relatively protected from tobacco smoke (SI=-0.93%), while African-American women appeared most susceptible (SI=-1.42%). CONCLUSIONS: There are important differences in racial and gender susceptibility to tobacco smoke among patients with COPD. African-American females appear to be at highest risk and may benefit most from smoking cessation.
BACKGROUND: Although chronic obstructive pulmonary disease (COPD) has been considered a disease of Caucasian men, recent data show mortality rising faster among women and African-Americans. Some have suggested these groups are more susceptible to tobacco smoke. We examined this issue in our own population of COPDpatients. METHODS: Beginning in March 2003 we prospectively developed a COPD research database to facilitate recruitment for clinical trials. Enrollees are recruited from clinics and paid advertising and their demographics, medical/smoking histories, and spirometric data are recorded. We examined the smoking histories and pulmonary function of enrollees over 45, with 20 pack-years of smoking, FEV(1)/FVC (forced expiratory volume forced vital capacity) <0.70, and a race-adjusted post-bronchodilator FEV(1)<80%. The primary outcome was the loss of lung function per pack-year smoked, or Susceptibility Index (SI), calculated using the formula: (% predicted FEV(1)-100)/pack-years. RESULTS: A total of 585 patients enrolled during the study period and 330 met our inclusion criteria. Caucasians were older than African-Americans (63 vs. 58, P=0.0003) and had more pack-years of smoking (57 vs. 43, P=0.0003). There were no differences in lung function or bronchodilator reversibility among the racial or gender subgroups. Caucasians had less loss of lung function per pack-year smoked than African-Americans (SI=-1.02% vs. -1.34%, P=0.007) and men less than women (SI=-0.98% vs. -1.21%, P=0.001). Caucasian males appeared relatively protected from tobacco smoke (SI=-0.93%), while African-American women appeared most susceptible (SI=-1.42%). CONCLUSIONS: There are important differences in racial and gender susceptibility to tobacco smoke among patients with COPD. African-American females appear to be at highest risk and may benefit most from smoking cessation.
Authors: Emily S Wan; John E Hokanson; James R Murphy; Elizabeth A Regan; Barry J Make; David A Lynch; James D Crapo; Edwin K Silverman Journal: Am J Respir Crit Care Med Date: 2011-04-14 Impact factor: 21.405
Authors: MeiLan K Han; Douglas Curran-Everett; Mark T Dransfield; Gerard J Criner; Lening Zhang; James R Murphy; Nadia N Hansel; Dawn L DeMeo; Nicola A Hanania; Elizabeth A Regan; Barry J Make; Fernando J Martinez; Gloria E Westney; Marilyn G Foreman Journal: Chest Date: 2011-06-02 Impact factor: 9.410
Authors: Chinedu O Ejike; Mark T Dransfield; Nadia N Hansel; Nirupama Putcha; Sarath Raju; Carlos H Martinez; MeiLan K Han Journal: Am J Respir Crit Care Med Date: 2019-08-15 Impact factor: 21.405
Authors: Tadahiro Goto; Mohammad Kamal Faridi; Koichiro Gibo; Sengwee Toh; Nicola A Hanania; Carlos A Camargo; Kohei Hasegawa Journal: Respir Med Date: 2017-07-26 Impact factor: 3.415
Authors: Ayodeji Adegunsoye; Justin M Oldham; Shashi K Bellam; Jonathan H Chung; Paul A Chung; Kathleen M Biblowitz; Steven Montner; Cathryn Lee; Scully Hsu; Aliya N Husain; Rekha Vij; Gokhan Mutlu; Imre Noth; Matthew M Churpek; Mary E Strek Journal: Eur Respir J Date: 2018-06-14 Impact factor: 16.671
Authors: Rhea Powell; Duncan Davidson; Jasmin Divers; Ani Manichaikul; J Jeffrey Carr; Robert Detrano; Eric A Hoffman; Rui Jiang; Richard A Kronmal; Kiang Liu; Naresh M Punjabi; Eyal Shahar; Karol E Watson; Jerome I Rotter; Kent D Taylor; Stephen S Rich; R Graham Barr Journal: Thorax Date: 2013-04-12 Impact factor: 9.139